UK markets close in 5 hours 13 minutes

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.8800-0.0500 (-2.59%)
At close: 04:00PM EST
1.8500 -0.03 (-1.60%)
Pre-market: 04:43AM EST
Full screen
Loading interactive chart…
  • Globe Newswire

    atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

    GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day.Final results demonstrate target engagement of GRX-917 via dose-related activation of quantitative electroencephalography (qEEG) frontal beta power, a biomarker for GABA-A receptor-associated anxiolytic activity, consistent with GRX-917’s puta

  • Globe Newswire

    atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

    NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Sc

  • Globe Newswire

    atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101

    - This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 - KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models - An assessment of the respiratory impact of KUR-101 was inconclusive as the positive control, oxycodone, failed to separate from placebo - KUR-101, a deuterated derivative of mitragynine, is a low-potency, partial mu-opioid receptor (MOR) agonist designed to prod